RAS mutation
|
Thyroid Gland Medullary Carcinoma
|
RAS mutation
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib capsule Sensitive: A2 - Guideline
|
cabozantinib capsule Sensitive: A2 - Guideline
|
RAS mutation
|
AML
|
RAS mutation
|
AML
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
RAS mutation
|
Multiple Myeloma
|
RAS mutation
|
Multiple Myeloma
|
selinexor Sensitive: C3 – Early Trials
|
selinexor Sensitive: C3 – Early Trials
|
RAS mutation
|
CRC
|
RAS mutation
|
CRC
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|
RAS mutation
|
CRC
|
RAS mutation
|
CRC
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
RAS mutation
|
Thyroid Gland Anaplastic Carcinoma
|
RAS mutation
|
Thyroid Gland Anaplastic Carcinoma
|
atezolizumab + cobimetinib Sensitive: C3 – Early Trials
|
atezolizumab + cobimetinib Sensitive: C3 – Early Trials
|
RAS mutation
|
CRC
|
RAS mutation
|
CRC
|
pembrolizumab + selinexor Sensitive: C3 – Early Trials
|
pembrolizumab + selinexor Sensitive: C3 – Early Trials
|
RAS mutation
|
Thyroid Gland Carcinoma
|
RAS mutation
|
Thyroid Gland Carcinoma
|
trametinib Sensitive: C3 – Early Trials
|
trametinib Sensitive: C3 – Early Trials
|
RAS mutation
|
CRC
|
RAS mutation
|
CRC
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
RAS mutation
|
CRC
|
RAS mutation
|
CRC
|
bevacizumab Resistant: C3 – Early Trials
|
bevacizumab Resistant: C3 – Early Trials
|
RAS mutation
|
Rectal Cancer
|
RAS mutation
|
Rectal Cancer
|
SOXIRI Sensitive: C3 – Early Trials
|
SOXIRI Sensitive: C3 – Early Trials
|
RAS mutation
|
Rectal Cancer
|
RAS mutation
|
Rectal Cancer
|
FOLFOXIRI Sensitive: C3 – Early Trials
|
FOLFOXIRI Sensitive: C3 – Early Trials
|
RAS mutation
|
AML
|
RAS mutation
|
AML
|
mTOR inhibitor Resistant: D – Preclinical
|
mTOR inhibitor Resistant: D – Preclinical
|